Supplemental Methods from Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
Year: 2023
Type: supplementary-materials
Abstract: The following information describes additional study design criteria and safety considerations used in the phase 1 clinical trial of RG7112 in patients with hematological malignancies
Authors: Michael Andreeff, Kevin R. Kelly, Karen Yee, Sarit Assouline, Roger Strair, Leslie Popplewell, David Bowen, Giovanni Martinelli, Mark W. Drummond, Paresh Vyas, Mark Kirschbaum, Swaminathan Padmanabhan Iyer, Vivian Ruvolo, Graciela M. Nogueras González, Xuelin Huang, Gong Chen, Bradford Graves, Steven Blotner, Peter Bridge, Lori Jukofsky, Steve Middleton, Monica Reckner, Ruediger Rueger, Jianguo Zhi, Gwen Nichols, Kensuke Kojima
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361919679